Cargando…

Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C

Hepatitis C virus (HCV) is estimated to affect up to 150 million people worldwide. Despite worldwide prevalence, treatment modalities prior to 2011 remained suboptimal, with low virologic response rates and intolerable side effect profiles. Fortunately, the landscape of treatment for chronic hepatit...

Descripción completa

Detalles Bibliográficos
Autores principales: Bell, Allison M., Wagner, Jamie L., Barber, Katie E., Stover, Kayla R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925941/
https://www.ncbi.nlm.nih.gov/pubmed/27403342
http://dx.doi.org/10.1155/2016/3852126
_version_ 1782440012673974272
author Bell, Allison M.
Wagner, Jamie L.
Barber, Katie E.
Stover, Kayla R.
author_facet Bell, Allison M.
Wagner, Jamie L.
Barber, Katie E.
Stover, Kayla R.
author_sort Bell, Allison M.
collection PubMed
description Hepatitis C virus (HCV) is estimated to affect up to 150 million people worldwide. Despite worldwide prevalence, treatment modalities prior to 2011 remained suboptimal, with low virologic response rates and intolerable side effect profiles. Fortunately, the landscape of treatment for chronic hepatitis C has rapidly evolved since the introduction of HCV NS3/4 protease inhibitors in 2011. Elbasvir, a NS5A inhibitor, combined with grazoprevir, a NS3/4A protease inhibitor, is the latest FDA-approved therapy for patients with genotype 1 or 4 chronic hepatitis C, with or without compensated cirrhosis. This review will focus on the current literature and clinical evidence supporting elbasvir/grazoprevir as first-line therapy in patients with genotypes 1 and 4 chronic hepatitis C.
format Online
Article
Text
id pubmed-4925941
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-49259412016-07-11 Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C Bell, Allison M. Wagner, Jamie L. Barber, Katie E. Stover, Kayla R. Int J Hepatol Review Article Hepatitis C virus (HCV) is estimated to affect up to 150 million people worldwide. Despite worldwide prevalence, treatment modalities prior to 2011 remained suboptimal, with low virologic response rates and intolerable side effect profiles. Fortunately, the landscape of treatment for chronic hepatitis C has rapidly evolved since the introduction of HCV NS3/4 protease inhibitors in 2011. Elbasvir, a NS5A inhibitor, combined with grazoprevir, a NS3/4A protease inhibitor, is the latest FDA-approved therapy for patients with genotype 1 or 4 chronic hepatitis C, with or without compensated cirrhosis. This review will focus on the current literature and clinical evidence supporting elbasvir/grazoprevir as first-line therapy in patients with genotypes 1 and 4 chronic hepatitis C. Hindawi Publishing Corporation 2016 2016-06-15 /pmc/articles/PMC4925941/ /pubmed/27403342 http://dx.doi.org/10.1155/2016/3852126 Text en Copyright © 2016 Allison M. Bell et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Bell, Allison M.
Wagner, Jamie L.
Barber, Katie E.
Stover, Kayla R.
Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C
title Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C
title_full Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C
title_fullStr Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C
title_full_unstemmed Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C
title_short Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C
title_sort elbasvir/grazoprevir: a review of the latest agent in the fight against hepatitis c
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925941/
https://www.ncbi.nlm.nih.gov/pubmed/27403342
http://dx.doi.org/10.1155/2016/3852126
work_keys_str_mv AT bellallisonm elbasvirgrazoprevirareviewofthelatestagentinthefightagainsthepatitisc
AT wagnerjamiel elbasvirgrazoprevirareviewofthelatestagentinthefightagainsthepatitisc
AT barberkatiee elbasvirgrazoprevirareviewofthelatestagentinthefightagainsthepatitisc
AT stoverkaylar elbasvirgrazoprevirareviewofthelatestagentinthefightagainsthepatitisc